0 CHECKOUT

Sarcoidosis - Pipeline Review, H2 2015

  • ID: 3440626
  • September 2015
  • 64 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Celgene Corporation
  • Novartis AG
  • PharmaIN Corporation
  • MORE

Sarcoidosis - Pipeline Review, H2 2015

Summary

The report ‘Sarcoidosis - Pipeline Review, H2 2015’, provides an overview of the Sarcoidosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Sarcoidosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sarcoidosis and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Celgene Corporation
  • Novartis AG
  • PharmaIN Corporation
  • MORE

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Sarcoidosis Overview

Therapeutics Development

Pipeline Products for Sarcoidosis - Overview

Pipeline Products for Sarcoidosis - Comparative Analysis

Sarcoidosis - Therapeutics under Development by Companies

Sarcoidosis - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Sarcoidosis - Products under Development by Companies

Sarcoidosis - Companies Involved in Therapeutics Development

Araim Pharmaceuticals Inc.

Celgene Corporation

FirstString Research, Inc.

Novartis AG

PharmaIN Corporation

Sarcoidosis - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

ABS-11 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

apremilast - Drug Profile

Product Description

Mechanism of Action

R&D Progress

canakinumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CC-220 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

cibinetide - Drug Profile

Product Description

Mechanism of Action

R&D Progress

eprodisate disodium - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PGC-VIP - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Synthetic Peptide for Sarcoidosis - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Sarcoidosis - Recent Pipeline Updates

Sarcoidosis - Dormant Projects

Sarcoidosis - Discontinued Products

Sarcoidosis - Product Development Milestones

Featured News & Press Releases

Aug 12, 2015: BELLUS Health narrows timelines for the Phase III study for KIACTA

Oct 28, 2014: Araim Pharmaceuticals Given FDA Fast Track Designation to ARA 290 for the Treatment of Sarcoidosis-associated Small Fiber Neuropathy

Sep 19, 2014: Transparency Life Sciences To Conduct Sarcoidosis Trial For Auven Therapeutics' Kiacta™ Using Crowdsourcing And Telemonitoring

Oct 10, 2013: Araim Pharmaceuticals’ ARA 290, a Peptide Engineered to Activate Innate Repair, Receives Orphan Drug Designation from the European Commission

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Sarcoidosis, H2 2015

Number of Products under Development for Sarcoidosis - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

Sarcoidosis - Pipeline by Araim Pharmaceuticals Inc., H2 2015

Sarcoidosis - Pipeline by Celgene Corporation, H2 2015

Sarcoidosis - Pipeline by FirstString Research, Inc., H2 2015

Sarcoidosis - Pipeline by Novartis AG, H2 2015

Sarcoidosis - Pipeline by PharmaIN Corporation, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Sarcoidosis Therapeutics - Recent Pipeline Updates, H2 2015

Sarcoidosis - Dormant Projects, H2 2015

Sarcoidosis - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Sarcoidosis, H2 2015

Number of Products under Development for Sarcoidosis - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

Araim Pharmaceuticals Inc.
Celgene Corporation
FirstString Research, Inc.
Novartis AG
PharmaIN Corporation

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Sanofi S.A.
  • GlaxoSmithKline PLC
  • Astrazeneca PLC
  • Invacare Corporation
  • Boehringer Ingelheim GmbH
  • Takeda Pharmaceutical Company Limited